论文部分内容阅读
目的分析不同剂量丙种球蛋白治疗小儿川崎病的临床效果,探讨最佳治疗剂量。方法 94例小儿川崎病患儿,随机分为对照组(常规剂量丙种球蛋白治疗)与观察组(大剂量丙种球蛋白治疗),各47例。比较两组的临床效果。结果观察组的治疗总有效率为93.62%,显著高于对照组的80.85%;观察组的冠状动脉损害发生率为8.51%,显著低于对照组的23.40%;组间对比,差异均具有统计学意义(χ~2=9.06、10.25,P<0.05)。观察组的黏膜充血、皮疹及手足皮肤症状消退时间分别为(2.33±1.08)、(2.12±2.54)、(2.59±0.94)d,均显著短于对照组的(4.42±1.23)、(3.09±2.15)、(4.32±1.43)d,组间对比,差异均具有统计学意义(t=9.69、8.83、11.95,P<0.05)。结论大剂量丙种球蛋白治疗小儿川崎病的效果更为确切,与常规剂量相比更有利于患儿的血糖控制,安全可靠,具有临床推广应用的意义与价值。
Objective To analyze the clinical effects of different dosages of gamma globulin in treatment of pediatric Kawasaki disease and to explore the best therapeutic dose. Methods Ninety-four children with Kawasaki disease were randomly divided into control group (conventional treatment with gamma globulin) and observation group (high-dose gamma-globulin treatment), 47 cases in each. The clinical effects of the two groups were compared. Results The total effective rate of the observation group was 93.62%, which was significantly higher than that of the control group (80.85%). The incidence of coronary artery lesion in the observation group was 8.51%, which was significantly lower than that of the control group (23.40%). Significance (χ ~ 2 = 9.06, 10.25, P <0.05). Mucosal hyperemia, rash and hand-foot skin symptoms in the observation group were (2.33 ± 1.08), (2.12 ± 2.54) and (2.59 ± 0.94) d respectively, which were significantly shorter than those in the control group (4.42 ± 1.23, 3.09 ± 2.15) and (4.32 ± 1.43) d, respectively. The differences between the two groups were statistically significant (t = 9.69, 8.83, 11.95, P <0.05). Conclusion The effect of high-dose gamma globulin on children with Kawasaki disease is more accurate. Compared with the conventional dose, it is more beneficial to the control of children’s blood sugar, safe and reliable, and has the clinical significance of promotion and application.